[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100421985":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":31,"locations":41,"responsibleParty":60,"collaborators":64,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":80,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":35,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":35,"overallStatus":98,"whyStopped":35,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Turku University Hospital","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"EVLA only","ACTIVE_COMPARATOR","Only main trunk\u002Ftrunks with venous reflux will be treated",[13],"Procedure: Endovenous laser ablation",{"label":15,"type":10,"description":16,"interventionNames":17},"EVLA and sclerotherapy of tributaries","Main trunk\u002Ftrunks with venous reflux will be treated combined with foam sclerotherapy",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"PROCEDURE","Endovenous laser ablation","The aim is to combine the significance of for sclerotherapy at the primary EVLA treatment",[15,9],[25],"Endovenous laser ablation combined with foam sclerotherapy of varicose tributaries",[27],{"name":28,"affiliation":29,"role":30},"Harri Hakovirta, Professor","University of Turku","STUDY_CHAIR",[32,37],{"name":28,"role":33,"phone":34,"phoneExt":35,"email":36},"CONTACT","+358405918811",null,"haheha@utu.fi",{"name":38,"role":33,"phone":39,"phoneExt":35,"email":40},"Khalil Firoozi, MD","+35823130000","khalil.firoozi@tyks.fi",[42],{"facility":5,"status":35,"city":43,"state":35,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Turku","20520","Finland","FI",{"type":48,"coordinates":49},"Point",[50,51],22.26869,60.45148,{"lat":51,"lon":50},[54,56,57],{"name":28,"role":33,"phone":39,"phoneExt":35,"email":55},"harri.hakovirta@tyks.fi",{"name":38,"role":33,"phone":39,"phoneExt":35,"email":40},{"name":58,"role":59,"phone":35,"phoneExt":35,"email":35},"Jaakko Viljamaa, MD","SUB_INVESTIGATOR",{"type":61,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":35,"oldOrganization":35},"PRINCIPAL_INVESTIGATOR","Khalil Firoozi","MD",[65,68,70,72,74,76],{"name":66,"class":67},"Helsinki University Central Hospital","OTHER",{"name":69,"class":67},"Oulu University Hospital",{"name":71,"class":67},"Tampere University Hospital",{"name":73,"class":67},"Päijänne Tavastia Central Hospital",{"name":75,"class":67},"Satasairaala",{"name":77,"class":67},"Vaasa Central Hospital, Vaasa, Finland","100421985","evla-and-optimal-timing-of-sclerotherapy-100421985",false,"NCT04774939","EVLA and Optimal Timing of Sclerotherapy","FinnTrunk, EVLA and Optimal Timing of Sclerotherapy","FinnTrunk","Inclusion Criteria:\n\n* Varicose disease of lower extremity caused by reflux of VSM, SSV or AASV to be treated with EVLA. Age over 18 years. Clinical symptoms C2-3.\n\nExclusion Criteria:\n\n* No severe comorbidities. Previous DVT.","ALL","18 Years","99 Years",{"count":90,"type":91},350,"ESTIMATED","INTERVENTIONAL",[94],"NA","The aim of the study is to investigate the optimal timing of sclerotherapy for treatment of varicose tributaries on EVLA (endogenous laser ablation) patients.",[97],"Venous Reflux","NOT_YET_RECRUITING","2021-02-24",{"date":101,"type":102},"2021-03-01","ACTUAL",{"date":104,"type":91},"2021-03-15",{"date":106,"type":91},"2030-03-15",{"name":5,"class":6},1]